Pregnancy and neonatal safety outcomes of timing of initiation of daily oral tenofovir disoproxil fumarate and emtricitabine pre-exposure prophylaxis for HIV prevention (CAP016): an open-label, randomised, non-inferiority trial

Background The safety of tenofovir disoproxil fumarate and emtricitabine as pre-exposure prophylaxis (PrEP) in pregnant women not living with HIV is uncertain.We aimed to compare pregnancy and neonatal outcomes in women exposed and not exposed to PrEP during pregnancy.Methods In this single-site, open-label, randomised, non-inferiority trial in Durban, South Africa, we evaluated pregnancy and neonatal outcomes in pregnant women aged 18 years or older, not living with HIV, and at 14-28 weeks' gestation at the time of enrolment. Eligible participants were randomly assigned (1:1) using a computer-generated permuted block (block size of ten) randomisation list to immediate initiation or deferred initiation of PrEP until breastfeeding cessation. Participants in the immediate PrEP group received a monthly supply of once daily oral tenofovir disoproxil fumarate 300 mg and emtricitabine 200 mg. Participants in the deferred PrEP group received standard of care for HIV prevention. The primary outcomes were the occurrence of preterm live birth (<37 weeks gestational age) and very preterm birth (<34 weeks gestational age) determined by menstrual dating, low birthweight (<2500 g), very low birthweight (<1500 g), stillbirth (>= 20 weeks gestational age), and small for gestational age (birthweight less than the tenth percentile). Post-natal safety outcomes will be reported elsewhere. We used binomial regression models to estimate risk differences and two-sided 90% CIs. Immediate PrEP was non-inferior to deferred PrEP if the upper bound of the 90% CI of the risk difference was less than the upper predefined non-inferiority margin for preterm birth (7 center dot 5%), very preterm birth (2 center dot 6%), low birthweight (5 center dot 5%), very low birthweight (1 center dot 2%), stillbirth (1 center dot 0%), and small for gestational age (3 center dot 7%). All outcomes were analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT3227731.Findings Between Sept 25, 2017, and Dec 6, 2019, we screened 693 women, of whom 540 were randomly assigned to immediate PrEP (n=271) or deferred PrEP (n=269). The median gestational age was 19 weeks (IQR 15-23 for immediate PrEP and 16-23 for deferred PrEP). The risk difference between the immediate PrEP group and the deferred PrEP group for preterm birth was -4 center dot 7% (90% CI -10 center dot 7 to 1 center dot 2; immediate PrEP was non-inferior), for very preterm birth was 0 center dot 6% (-3 center dot 4 to 4 center dot 6; upper limit exceeded the non-inferiority margin), for low birthweight was 2 center dot 5% (-1 center dot 6 to 6 center dot 6; upper limit exceeded the non-inferiority margin), for very low birthweight was 0% (-1 center dot 4 to 1 center dot 4; upper limit exceeded the non-inferiority margin), for stillbirth was 1 center dot 2% (-1 center dot 5 to 3 center dot 8; upper limit exceeded the non-inferiority margin), and for small for gestational age was 0 center dot 9% (-1 center dot 2 to 2 center dot 9; immediate PrEP was non-inferior).Interpretation In our study, PrEP was not associated with preterm birth or small for gestational age infants. Our data support the use of tenofovir disoproxil fumarate and emtricitabine in pregnancy and our reassuring findings can be used to allay safety concerns among pregnant women.Copyright (c) 2023 Published by Elsevier Ltd. All rights reserved.